Skip to content
  • Sunday, 26 July 2026
  • 3:15 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?
Laboratory Automation & Robotics

First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?

Lana Keisha Mar 27, 2026 0

For decades, the medical community has grappled with the persistent challenge of mood disorders, offering successive waves of antidepressants that,…

Read More
Laboratory Automation & Robotics

First Phase 3 psilocybin data clears the bar for treatment-resistant depression, but how high was the bar?

Lana Keisha Mar 20, 2026 0

The landscape of mental health treatment witnessed a significant development on February 17, 2026, as Compass Pathways, a leading mental…

Read More

Posts pagination

1 2
CEPI Fast-Tracks Ebola Vaccine Candidates from IAVI, Moderna, and OxfordPython Blood Reveals Novel Appetite Suppressant, Offering New Hope for Weight Loss and Metabolic Health TherapiesExplosive Growth and Evolutionary Timelines of Chronic Myeloid Leukemia Revealed Through Genomic MappingETH Zurich Researchers Engineer Single Atom Catalyst for Efficient Conversion of Carbon Dioxide into Sustainable Methanol
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ